PharmaHHS Opens Drug Price Dickering
With newfound authority granted by the IRA, HHS bids on 10 drugs selected for the first round of negotiations.
PharmaThe FTC Is Attacking Drugmakers' 'Patent Thickets'
Regulators say drugmakers illegitimately use the patents to prevent competitors from offering cheaper generics.
PharmaSave Billions or Stick with Humira? Drug Brokers Steer Americans to the Costly Choice
The biggest hitch seems to be the PBMs.
Supply ChainECRI Honors 12 Hospital Supply Chains
The award recognizes providers for excellence in their supply chain processes.
PharmaPBMs, the Brokers Who Control Drug Prices, Finally Get Washington's Attention
After years of thundering against drugmakers, Congress and the administration have now focused on regulating PBMs.
PharmaCMS Rolls Out 3 Medicare Drug Savings Models
The models were authorized under an executive order by President Joe Biden to 'complement' drug cost-savings provisions in the Inflation...
PharmaAmazon Pharmacy Launches Very, Very Low-Cost Prescription Drug Service
RxPass will cost $5 a month for an unlimted supply of ALL commonly used drugs in its generic and off-brand...
PayerBiosimilar Drugs Are Cheaper Than Biologics. Are They Similar Enough to Switch?
The U.S. has been slower to adopt biosimilar drugs since the first such medicine was approved in 2015.
StrategyU.S. Prescription Drugs Cost Highest in the World, By Far
A RAND study shows the gap is even wider for brand-name drugs, with U.S. prices averaging 3.44 times those of...
StrategyCalifornia Rx: State May Dive Into Generic Drug Market
A bill, SB-852, opens the door for California to make its own generic drugs in the future. Gov. Gavin Newsom...
Strategy2021 Health Plans Granted Leeway to Limit Consumers' Benefit from Drug Coupons
Advocates for consumers with chronic conditions say the rule will make it harder for patients who rely on very expensive...
StrategySandoz Will Pay $195M to Settle Price Fixing Charges
It's the seventh such settlement reached by DOJ's Antitrust Division in its ongoing probe of the generic pharmaceutical industry.